Evidence mapPaperPMID 40535330Full record

ArticleFrontiers in endocrinology2025

Visceral adiposity loss is associated with improvement in cardiometabolic markers: findings from a dietary intervention study.

Shazana Rifham Abdullah, Ahmad Kamil Nur Zati Iwani, Liyana Ahmad Zamri, Ruziana Mona Wan Mohd Zin, Norhashimah Abu Seman, Nur Azlin Zainal Abidin, Siti Sarah Hamzah, Nur Hayati Azizul, Azahadi Omar, Zamtira Seman and 2 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shazana Rifham AbdullahInstitute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Ahmad Kamil Nur Zati IwaniInstitute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Liyana Ahmad ZamriInstitute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Ruziana Mona Wan Mohd ZinInstitute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Norhashimah Abu SemanInstitute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Nur Azlin Zainal AbidinInstitute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Siti Sarah HamzahInstitute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Nur Hayati AzizulInstitute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Azahadi OmarSector for Biostatistics and Data Repository, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Zamtira SemanSector for Biostatistics and Data Repository, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.
Abqariyah YahyaDepartment of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Mohd Fairulnizal Md NohInstitute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Shah Alam, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Visceral adiposity is closely linked with cardiometabolic disorders, but evidence on the extent of visceral fat loss required for significant improvement in cardiometabolic markers remains limited. This study aims to investigate the association between visceral fat area (VFA) reductions and improvements in cardiometabolic markers following a 3-month dietary intervention. Methods: A total of 175 adults with overweight and obesity were involved in this non-randomized controlled trial. Data on sociodemographic, anthropometric, body composition and biochemistry were collected at baseline and after 3 months of intervention. The multiple logistic regression analysis was conducted to determine the association between VFA loss (no loss, < 5% loss, and ≥ 5% loss) and improvement in cardiometabolic markers. For each cardiometabolic marker, an improvement surpassing the minimum threshold of the third tertile was classified as a good improvement. Results: Compared to those with no VFA loss, participants with VFA loss of ≥ 5% were significantly associated with a higher improvement in waist circumference (OR 2.97, 95% CI 1.16-7.64), high-density lipoprotein cholesterol (HDL-C) (OR 4.19, 95% CI 1.58-11.14), triglycerides (OR 3.01, 95% CI 1.14-7.92), and glycated hemoglobin (HbA1C) (OR 2.95, 95% CI 1.12-7.79). Other than that, those with < 5% VFA loss were 3.6 times more likely to have a higher improvement in HDL-C compared to those with no VFA loss (OR 4.08, 95% CI 1.36-12.22). Conclusion: This study found that the magnitude of VFA loss is an independent determinant of improvements in cardiometabolic markers and should be set as a clear target when designing obesity prevention programs.

Indexed as

BiomarkersCardiovascular DiseasesIntra-Abdominal FatObesityObesity, AbdominalOverweightWeight LossAdiposityAdultCholesterol, HDLFemaleGlycated HemoglobinHumansMaleMiddle AgedTriglyceridesBiomarkersCholesterol, HDLGlycated HemoglobinTriglyceridescardiometabolic markersinsulin resistanceintermittent fastinglipid profilesvisceral adiposityvisceral fat area

Identifiers

PMID40535330
PMCPMC12173930

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.